Latest news with #JohnSheridan
Business Wire
20-06-2025
- Business
- Business Wire
Tandem Diabetes Care Announces t:slim X2 ™ Insulin Pump Compatibility with Abbott's FreeStyle Libre® 3 Plus Sensor in the United States
SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology now works with Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring (CGM) sensor. The Company has initiated an early access program in the United States (U.S.), and intends to scale availability in the second half of 2025. 'This is an exciting first step in our strategy to connect Tandem's portfolio of insulin pumps to Abbott's FreeStyle Libre 3 Plus sensors worldwide.' - John Sheridan, president and chief executive officer of Tandem Diabetes Care. 'Diabetes management is not one-size-fits-all and it is critical for people living with diabetes to be able to personalize their AID systems to fit their unique healthcare and lifestyle needs,' said Dr. Jordan Pinsker, chief medical officer of Tandem Diabetes Care. 'The American Diabetes Association recommends AID systems as the preferred insulin delivery method in people with type 1 and other types of insulin-deficient diabetes, and this integration with Abbott's latest generation sensor allows even more CGM users to access the life-changing benefits of our Control-IQ+ technology.' The FreeStyle Libre 3 Plus sensor has an extended 15-day wear time, transmitting automatic glucose readings every minute directly to the pump. This data is also available to view on the Tandem t:slim mobile app, providing users with multiple, convenient ways to access their current glucose trend. The t:slim X2 insulin pump is powered by Control-IQ+ technology, the latest generation of Tandem's advanced hybrid closed-loop algorithm, which adjusts insulin every 5 minutes based on predicted glucose values. It's the only system with the unique AutoBolus™ feature that calculates and delivers a correction bolus to help with missed meal boluses.* Control-IQ+ is easy to start, use, and personalize, and this latest integration works with the FreeStyle Libre 3 Plus sensor and extends its benefits to even more people with diabetes. 'This is an exciting first step in our strategy to connect Tandem's portfolio of insulin pumps to Abbott's FreeStyle Libre 3 Plus sensors worldwide,' said John Sheridan, president and chief executive officer of Tandem Diabetes Care. 'We look forward to expanding access to our t:slim X2 users outside of the U.S. beginning later this year.' When available, Tandem will email eligible users in the U.S. with more information.† About Tandem Diabetes Care Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company's pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit Follow Tandem Diabetes Care on X @tandemdiabetes; use #tslimX2 #TandemMobi and #TandemDiabetes. Follow Tandem Diabetes Care on Facebook at Follow Tandem Diabetes Care on LinkedIn at Forward Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, our ability to provide the software update for current t:slim X2 pump users and the t:slim X2 pumps pre-loaded with Freestyle Libre 3 Plus sensor integration software. These statements are subject to numerous risks and uncertainties, including our ability to sustain commercial scale manufacturing of the t:slim X2 pumps pre-loaded with Freestyle Libre 3 Plus sensor integration software, our ability to operate and maintain a system to facilitate online training for existing t:slim X2 pump customers upgrading their existing devices, and the risk that we may encounter other challenges that may delay the availability of the software update for current t:slim X2 pump users or the t:slim X2 pumps pre-loaded with Freestyle Libre 3 Plus sensor integration software. These and other risks are identified and described in greater detail under the 'Risk Factors' heading of our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Actual results could differ materially from those anticipated or projected in the forward-looking statements. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events, or other factors. Important Safety Information – FreeStyle Libre Systems Product for prescription only; for Important Safety Information, please visit Important Safety Information – Tandem Diabetes Care RX ONLY. The t:slim X2 pump with interoperable technology (the pump) and Control-IQ+ technology (Control-IQ+) are intended for single patient use. The pump and Control-IQ+ are indicated for use with NovoLog or Humalog U-100 insulin. t:slim X2 insulin pump: The pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater. Control-IQ+ technology: Control-IQ+ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ+ technology is intended for the management of Type 1 diabetes mellitus in persons 2 years of age and greater and of Type 2 diabetes mellitus in persons 18 years of age and greater. WARNING: Control-IQ+ should not be used in anyone under the age of 2 years old with Type 1 diabetes or under the age of 18 years old with Type 2 diabetes. It should also not be used in patients who require less than a total daily insulin dose of 5 units of insulin per day or who weigh less than 20 pounds (9 kilograms), as those are the required minimum values needed for Control-IQ+ to operate safely. Users of the pump and Control-IQ+ must: use the insulin pump, iCGM, and all other system components in accordance with their respective instructions for use. Failure to follow these instructions for use could result in an over delivery or under delivery of insulin. This can cause hypoglycemia (low BG) or hyperglycemia (high BG) events. Visit for additional important safety information. © 2025 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ+, t:slim X2, t:slim, and Tandem Mobi are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. All other third-party marks are the property of their respective owners. * If glucose values are predicted to be above 180 mg/dL (or 10.0 mmol/L), Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 110 mg/dL (or 6.1 mmol/L) and delivers 60% of that value. † Future updates for all or some Tandem products may not be developed and may not be offered everywhere and would be subject to applicable regulatory approvals. Software updates are only available to customers who are in warranty at the time they update their pump. Additional training may be required to access certain software updates. Charges may apply. Tandem may discontinue select software and features over time at its discretion.
Yahoo
17-06-2025
- Business
- Yahoo
Abbott, Tandem Diabetes Care Partner For Glucose-Ketone Sensor for Diabetes Management
Abbott Laboratories (NYSE:ABT) is one of the best stocks to buy for beginners now. On June 10, Tandem Diabetes Care Inc. (NASDAQ:TNDM) announced a new agreement with Abbott to develop and commercialize integrated diabetes solutions. The collaboration will combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems, with the aim of providing more comprehensive management options for individuals with diabetes. The Abbott sensor, which is currently under development, will feature combined glucose and ketone sensing technology. The primary goal of the integrated sensor is to help people living with diabetes detect early rises in ketone levels, and thereby enable them to take prompt action and potentially avoid life-threatening diabetic ketoacidosis/DKA. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. The President and CEO of Tandem Diabetes Care, John Sheridan, stated that integrating Tandem's advanced insulin delivery systems with Abbott's future dual glucose-ketone sensor has the potential to empower patients with diabetes to make faster, more informed decisions about their health, which would ultimately lead to improved outcomes. Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells health care products worldwide. Tandem Diabetes Care Inc. (NASDAQ:TNDM) designs, develops, and commercializes technology solutions for people living with diabetes. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Business Wire
10-06-2025
- Business
- Business Wire
Tandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor
SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes. The Abbott sensor, currently under development, will combine glucose and ketone sensing technology that aims to help people living with diabetes detect early ketone rise to avoid life-threatening diabetic ketoacidosis. "Integrating our advanced insulin delivery systems with Abbott's future glucose-ketone sensor has the potential to help empower people with diabetes to take faster, more informed action to protect their health and improve outcomes," said John Sheridan, president and chief executive officer. "We are excited to continue our partnership with Abbott and look forward to working with them to bring this new integration to customers in the future." About Tandem Diabetes Care, Inc. Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company's pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit Follow @TandemDiabetes on Facebook, Instagram, LinkedIn, TikTok, and X. Forward-looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, development plans to integrate Tandem insulin delivery systems with Abbott dual glucose and ketone sensing technology. These forward-looking statements are subject to numerous risks and uncertainties, including risks, for example, that technical challenges, clinical or regulatory hurdles or other factors may prevent or delay integration, as well as other risks identified in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents that we file with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Actual results could differ materially from those anticipated or projected in the forward-looking statements. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors. ©2025 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ+, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. All third-party marks are the property of their respective owners.
BBC News
30-05-2025
- Entertainment
- BBC News
Fondop's wall-mounted motivation to take Oldham up
Oldham Athletic's 116-year stay in the English Football League ended in ignominy in Latics picked up the unenviable record of becoming the first former Premier League club to drop out of the top four tiers of English years on from that chastening relegation, one man who has seen the club at its lowest ebb has set about leading the charge back to league Radio Manchester spoke to striker Mike Fondop about how he has motivated himself to lead Oldham to glory in Sunday's National League promotion final against Southend United at Wembley. The 31-year-old arrived at the club during Oldham's ill-fated 2022 season but injuries restricted him to just two the club losing its EFL status, Fondop stuck with the club and has scored 37 goals in 113 National League appearances what encouraged him to stay at Boundary Park?"The manager at the time, John Sheridan, called me after the end of the season and said 'I need you to come back. You owe me because I signed you and you only played two games. I want you to get this club back where it belongs'," Fondop said."So that has always been an objective because I came and I didn't have a chance to help them stay in League Two."The club doesn't belong in League Two, they belong higher than that but it is a step by step process."Between their relegation from League Two and the start of the following 2022-23 National League season, a takeover of the Latics by local businessman Frank Rothwell was ended Abdallah Lemsagam's tenure in control of the club and Fondop said that the difference between then and now is stark."The club is absolutely different now. The ownership now is more family orientated. The owners are approachable and want everyone to feel part of a family," he added."In the past it felt toxic. As a player I was focused on what I was signed to do but the environment at the time felt toxic. Now it is so different."If a club doesn't treat its players well you might think in the long run you can get away with it, you might for a period of time, but eventually it is going to affect results. Now the treatment is completely different." 'I wasn't even born last time Oldham won promotion' Oldham are not a club which have had much to celebrate in recent decades, having floated around the lower leagues of English football both before and after the turn of the millennium - having spent 21 years in the third tier prior to relegation to League Two in most recent promotion came in 1991 when they won the then-Division Two second tier recent record makes for grim reading. Their first season in the National League saw them finish 12th and was the first time they had finished in the top half of a division since said a team talk from boss Micky Mellon about how long it had been since the club had won promotion helped motivate him ahead of the trip to the capital."It has been 34 years since we experienced promotion. I'm 31 so last time they won promotion I wasn't even born," Fondop added."After the gaffer said that I went home and wrote down 34 years in bold on a piece of paper with my goals for the season and I put it on my kitchen wall. It's always in my mind."It's in my head every day because I want to be part of history and I want the fans to get back into the feeling of what Oldham deserves. It means more than people might think. It's in my kitchen until today and I'm not going to remove it until it is done."As for how he plans to ease his nerves ahead of running out at Wembley, Fondop has an eclectic and varied music taste."On gamedays I listen to gospel and that is what calms me," he said."I love Andrea Bocelli, Time To Say Goodbye is one of my favourites."I love jazz music as well, I don't have one specific type of song, I love a bit of everything. Usually in my downtime I can listen to opera and jazz. I don't like listening to things that give me headaches."
Agriland
22-04-2025
- Business
- Agriland
Planning approved to extend facilities at Ballyhaise
Teagasc has been granted planning permission by Cavan County Council to expand its facilities at Ballyhaise Agricultural College, Co. Cavan, including the construction of an extension to suckler sheds. The Agriculture and Food Development Authority was seeking permission for a suckler shed extension, a livestock underpass with an effluent tank and a sheep shed with underground slatted tanks. Planning was also approved for a wash and boot area, medicine store, toilet, office and training room and all associated site works. As part of the application for the development, Teagasc submitted its fertiliser plan for Ballyhaise Agricultural College to the council's planning department. Planning for the extension was granted subject to 22 conditions. Cavan County Council has ordered that the design and construction of all approvals shall be in accordance with the Department of Agriculture, Food and the Marine (DAFM) specifications. The college herd, which is spring calving, is part of the Teagasc Moorepark Dairy Research programme. Facilities include a modern 12 unit herringbone milking parlour with automatic drafting, slatted houses, calving pens and isolation boxes. Planning permission Meanwhile, planning permission has also been granted by Mayo County Council to construct an anaerobic digestion (AD) plant near Ballinrobe, Co. Mayo. The proposed AD plant on a site of approximately 4.4ha will take in 90,000 tonnes of locally sourced manure/slurry, whole crop silage and other organic material to produce biomethane. The planning application was submitted by local pig farmer John Sheridan and Nephin Renewable Gas and the application states that 71 local farmers are willing to supply feedstock to the proposed plant. The development would involve the construction of three digesters which would be around 16m in height, two digestate storage structures, two pump houses and two liquid feed tanks.
